Syndromic Multiplex Panels Markets. Strategies And Trends. Forecasts By Syndrome (Respiratory, Sepsis, Gi Etc.) By Place, By Product and by Country. With Market Analysis and Executive Guides. 7th Edition. 2026 To 2030

Table of Contents

1 Market Guides

• 1.1 Situation Analysis
• 1.2 Guide for Executives and Marketing Staff
• 1.3 Guide for Investment Analysts and Management Consultants

2 Introduction and Market Definition

• 2.1 What are Syndromic Multiplex Tests?
• 2.2 Syndromic Testing - the quiet revolution in diagnostics
  • 2.2.1 Syndromic Testing - more than Panels.
• 2.3 Market Definition
  • 2.3.1 Multiplex Market Size.
  • 2.3.2 Currency.
  • 2.3.3 Years.
• 2.4 Methodology
  • 2.4.1 Methodology
  • 2.4.2 Sources
  • 2.4.3 Authors
• 2.5 Perspective: Healthcare Spending
  • 2.5.1 Global Healthcare Spending
  • 2.5.2 Spending on Healthcare and Pharmaceuticals
  • 2.5.3 Spending on Diagnostics
  • 2.5.4 Important Role of Insurance for Medical Services

3 Infectious Disease

• 3.1 Infections - The Big Picture
• 3.2 The Pathogens
  • 3.2.1 Bacteria
  • 3.2.2 Fungi and Protozoa
  • 3.2.3 Viruses
  • 3.2.4 Prions
• 3.3 Symptoms and Syndromes
  • 3.3.1 Bacterial or viral
  • 3.3.2 Typical Viral Symptoms
  • 3.3.3 Typical Bacterial Symptoms
• 3.4 Disease
• 3.5 Transmission
• 3.6 Infectious Disease Diagnostics
  • 3.6.1 Microbial culture
  • 3.6.2 Microscopy
  • 3.6.3 Biochemical tests
  • 3.6.4 PCR-based diagnostics
  • 3.6.5 Metagenomic sequencing
• 3.7 Defining Infections
• 3.8 Syndromic Infection

4 Industry Overview

• 4.1 Players in a Dynamic Market
  • 4.1.1 Academic Research Lab
  • 4.1.2 Diagnostic Test Developer
  • 4.1.3 Instrumentation Supplier
  • 4.1.4 Chemical/Reagent Supplier
  • 4.1.5 Pathology Supplier
  • 4.1.6 Independent Clinical Laboratory
  • 4.1.7 Public National/regional Laboratory
  • 4.1.8 Hospital Laboratory
  • 4.1.9 Physicians Office Lab (POLS)
  • 4.1.10 Audit Body
  • 4.1.11 Certification Body
• 4.2 The Clinical Laboratory Market Segments
  • 4.2.1 Traditional Market Segmentation
  • 4.2.2 Laboratory Focus and Segmentation
  • 4.2.3 Segmenting the Syndromic Testing Market
• 4.3 Industry Structure
  • 4.3.1 Hospital Testing Share
  • 4.3.2 Economies of Scale
    • 4.3.2.1 Hospital vs. Central Lab
  • 4.3.3 Physician Office Lab's
  • 4.3.4 Physician's and POCT

5 Market Trends

• 5.1 Factors Driving Growth
  • 5.1.1 Speed of Diagnosis.
  • 5.1.2 Effect of Syndromic Testing on Costs.
  • 5.1.3 Point of Care Advantage.
  • 5.1.4 Accuracy and Diagnostic Risk.
  • 5.1.5 Single Visits.
  • 5.1.6 Improvement in Outcomes.
  • 5.1.7 Impact of the Pandemic.
• 5.2 Factors Limiting Growth
  • 5.2.1 Lower Prices.
  • 5.2.2 Administration/reimbursement.
  • 5.2.3 Infectious Disease is Declining But....
  • 5.2.4 Wellness Hurts.
  • 5.2.5 Economic Growth improves Living Standards.
  • 5.2.6 Impact of the Pandemic
• 5.3 Instrumentation, Automation and Diagnostic Trends
  • 5.3.1 Traditional Automation and Centralization
  • 5.3.2 The New Automation, Decentralization and Point of Care
  • 5.3.3 Instruments Key to Market Share
  • 5.3.4 Bioinformatics Plays a Role
  • 5.3.5 PCR Takes Command
  • 5.3.6 Next Generation Sequencing Fuels a Revolution
  • 5.3.7 NGS Impact on Pricing
  • 5.3.8 Whole Genome Sequencing, A Brave New World
  • 5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment
  • 5.3.10 Comparing Syndrome and Targeted Testing
  • 5.3.11 The Multiplex Paradigm Shift
  • 5.3.12 The Sepsis Testing Market - Bellwether for Syndromics
  • 5.3.13 The Single Visit and AntiMicrobial Resistance
  • 5.3.14 Syndromics drives POCT adoption.

6 Syndromic Testing Recent Developments

• 6.1 Recent Developments - Importance and How to Use This Section
  • 6.1.1 Importance of These Developments
  • 6.1.2 How to Use This Section
• 6.2 QIAGEN Gains U.S. Clearance of QIAstat-Dx Rise
• 6.3 Diasorin Gains Approbal for Gram-Positive Bloodstream Infection Panel
• 6.4 BioMerieux BioFire and SpotFire Gain Momentum
• 6.5 Advanced Biological Laboratories Inks Deal for Siemens PCR
• 6.6 FDA Clears Qiagen's Five-Target Syndromic GI Panel
• 6.7 BioMerieux Gets Clearance for Tropical Fever Panel
• 6.8 Clinical Diagnostics Growth Drives Rise in Qiagen's Q3 Revenues
• 6.9 Credo Preps MDx System, Multiplex Respiratory Test for US Launch
• 6.10 Diasorin Nabs Clearance for Expanded Respiratory Panel
• 6.11 Bosch, R-Biopharm to Invest Euro 150M in PCR Tests for Vivalytic MDx Platform
• 6.12 Cepheid Gets Waiver for Multiplex Vaginal Panel
• 6.13 BioMerieux Submits Application for Respiratory, Sore Throat Panel
• 6.14 Sensible Diagnostics Nabs Award for Respiratory Panel
• 6.15 Aptitude Medical Systems to Develop At-Home STI Test
• 6.16 Multiplex Meningitis/Encephalitis Panel Market Expanding
• 6.17 Burst Dx to Deliver Lab-Accurate ELISA-in-a-Cartridge
• 6.18 OpGen Seeking Approval for UTI Panel
• 6.19 Altratech to Enter MDx, POC Space by Supplanting PCR
• 6.20 BIOFIRE Announces New SPOTFIRER System
• 6.21 Cambridge Nucleomics to Develop 'Nanobait' Tech
• 6.22 Takara Bio Developing Multiplex Panels
• 6.23 Rover Diagnostics Developing Optical Multiplex PCR
• 6.24 Nanopath Secures Funding to Develop POC Dx
• 6.25 Genetic Signatures Wins Public Health Wales Contract
• 6.26 Qiagen Looks to Long-Term Growth
• 6.27 LexaGene Gets Investment
• 6.28 Seegene Multiplex COVID-19/Flu/RSV Test Receives Approval

7 Profiles of Key Syndromic Testing Companies

• 7.1 Key Companies - Importance and How to Use This Section
  • 7.1.1 Importance of These Players
  • 7.1.2 How to Use This Section
• 7.2 Abbott Laboratories
• 7.3 Accelerate Diagnostics
• 7.4 Ador Diagnostics
• 7.5 ADT Biotech
• 7.6 Advanced Biological Laboratories
• 7.7 Agilent
• 7.8 Akonni Biosystems
• 7.9 Altona Diagnostics
• 7.10 Alveo Technologies
• 7.11 Applied BioCode
• 7.12 Aptitude Medical Systems
• 7.13 Aureum Diagnostics
• 7.14 Aus Diagnostics
• 7.15 Autonomous Medical Devices
• 7.16 Baebies
• 7.17 Beckman Coulter Diagnostics (Danaher)
• 7.18 Becton, Dickinson and Company
• 7.19 Binx Health
• 7.20 Biocartis
• 7.21 BioFire Diagnostics (bioMerieux)
• 7.22 BioGX
• 7.23 bioMerieux Diagnostics
• 7.24 Bio-Rad Laboratories, Inc
• 7.25 Bosch Healthcare Solutions GmbH
• 7.26 Cepheid (Danaher)
• 7.27 Credo Diagnostics Biomedical
• 7.28 Cube Dx
• 7.29 Cue Health
• 7.30 Curetis (OpGen)
• 7.31 Detect
• 7.32 Diagenode Diagnostics (Hologic)
• 7.33 Diasorin S.p.A.
• 7.34 Domus Diagnostics
• 7.35 Enzo Biochem
• 7.36 Eurofins Scientific
• 7.37 Fluxergy
• 7.38 Fusion Genomics.
• 7.39 Genematrix
• 7.40 Genetic Signatures
• 7.41 GenMark Dx (Roche)
• 7.42 Great Basin Scientific, Inc
• 7.43 Grip Molecular Technologies
• 7.44 Hologic
• 7.45 Immunexpress
• 7.46 Inflammatix
• 7.47 Invetech
• 7.48 J&J Innovative Medicine
• 7.49 Karius
• 7.50 Linear Diagnostics
• 7.51 Lucira Health (Pfizer)
• 7.52 Maxim Biomedical
• 7.53 Meep
• 7.54 Meridian Bioscience
• 7.55 Millipore Sigma
• 7.56 Molbio Diagnostics
• 7.57 Nanomix
• 7.58 Novel Microdevices
• 7.59 Nuclein
• 7.60 OnsiteGene
• 7.61 Operon
• 7.62 Oxford Nanopore Technologies
• 7.63 Panagene
• 7.64 Primerdesign (Novacyt)
• 7.65 Prominex
• 7.66 Proof Diagnostics
• 7.67 Qiagen
• 7.68 QuantuMDx
• 7.69 QuidelOrtho
• 7.70 R-Biopharm AG
• 7.71 Revvity
• 7.72 Roche Diagnostics
• 7.73 Scope Fluidics
• 7.74 Seegene
• 7.75 Siemens Healthineers
• 7.76 Sona Nanotech
• 7.77 SpeeDx
• 7.78 Streamline Scientific
• 7.79 Sugentech
• 7.80 T2 Biosystems
• 7.81 Talis Biomedical
• 7.82 Thermo Fisher Scientific
• 7.83 Uniogen
• 7.84 VedaBio
• 7.85 Vela Diagnostics
• 7.86 Veramarx
• 7.87 Visby Medical
• 7.88 XCR Diagnostics

8 The Global Market for Syndromic Multiplex Diagnostics

• 8.1 Global Market Overview by Country
  • 8.1.1 Table - Global Market by Country
  • 8.1.2 Chart - Global Market by Country
• 8.2 Global Market by Syndrome - Overview
  • 8.2.1 Table - Global Market by Syndrome
  • 8.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
  • 8.2.3 Chart - Global Market by Syndrome - Base Year
  • 8.2.4 Chart - Global Market by Syndrome - End Year
  • 8.2.5 Chart - Global Market by Syndrome - Share by Year
  • 8.2.6 Chart - Global Market by Syndrome - Segments Growth
• 8.3 Global Market by Place - Overview
  • 8.3.1 Table - Global Market by Place
  • 8.3.2 Chart - Global Market by Place - Base/Final Year Comparison
  • 8.3.3 Chart - Global Market by Place - Base Year
  • 8.3.4 Chart - Global Market by Place - End Year
  • 8.3.5 Chart - Global Market by Place - Share by Year
  • 8.3.6 Chart - Global Market by Place - Segments Growth
• 8.4 Global Market by Product - Overview
  • 8.4.1 Table - Global Market by Product
  • 8.4.2 Chart - Global Market by Product - Base/Final Year Comparison
  • 8.4.3 Chart - Global Market by Product - Base Year
  • 8.4.4 Chart - Global Market by Product - End Year
  • 8.4.5 Chart - Global Market by Product - Share by Year
  • 8.4.6 Chart - Global Market by Product - Segments Growth

9 Global Syndromic Multiplex Markets - By Syndrome

• 9.1 Respiratory
  • 9.1.1 Table Respiratory - by Country
  • 9.1.2 Chart - Respiratory Growth
• 9.2 Gastrointestinal
  • 9.2.1 Table Gastrointestinal - by Country
  • 9.2.2 Chart - Gastrointestinal Growth
• 9.3 Blood
  • 9.3.1 Table Blood - by Country
  • 9.3.2 Chart - Blood Growth
• 9.4 Meningitis/Encephalitis
  • 9.4.1 Table Meningitis/Encephalitis - by Country
  • 9.4.2 Chart - Meningitis/Encephalitis Growth
• 9.5 Sexually Transmitted Disease
  • 9.5.1 Table Sexually Transmitted Disease - by Country
  • 9.5.2 Chart - Sexually Transmitted Disease Growth
• 9.6 Other Syndrome
  • 9.6.1 Table Other - by Country
  • 9.6.2 Chart - Other Growth

10 Global Syndromic Markets - by Place

• 10.1 Hospital Lab
  • 10.1.1 Table Hospital Lab - by Country
  • 10.1.2 Chart - Hospital Lab Growth
• 10.2 Outpatient Lab
  • 10.2.1 Table Outpatient Lab - by Country
  • 10.2.2 Chart - Outpatient Lab Growth
• 10.3 Point of Care
  • 10.3.1 Table Point of Care - by Country
  • 10.3.2 Chart - Point of Care Growth
• 10.4 Other Place
  • 10.4.1 Table Other - by Country
  • 10.4.2 Chart - Other Place Growth

11 Global Syndromic Markets - by Product

• 11.1 Instruments
  • 11.1.1 Table Instruments - by Country
  • 11.1.2 Chart - Instruments Growth
• 11.2 Cartridges
  • 11.2.1 Table Cartridges - by Country
  • 11.2.2 Chart - Cartridges Growth
• 11.3 Reagents
  • 11.3.1 Table Reagents - by Country
  • 11.3.2 Chart - Reagents Growth
• 11.4 Other Product
  • 11.4.1 Table Other Product - by Country
  • 11.4.2 Chart - Other Product Growth

12 Appendices

• 12.1 United States Medicare System: Clinical Laboratory Fees Schedule
• 12.2 The Most Used IVD Assays
• 12.3 The Highest Grossing Assays

Table of Tables

• Table 1 Market Players by Type
• Table 2 Clinical Laboratory Departments and Segments
• Table 3 Laboratory Management Focus - Different Approaches
• Table 4 Key Segmentation Variables Going Forward
• Table 5 Possible Market Segments of Syndromic Multiplex Market
• Table 6 Five Factors Driving Growth
• Table 7 How SMT Improves Outcomes
• Table 8 Four Factors Limiting Growth
• Table 9 Seven Key Diagnostic Laboratory Technology Trends
• Table 10 - Global Market by Region
• Table 11 Global Market by Syndrome
• Table 12 Global Market by Place
• Table 13 Global Market by Product
• Table 14 Respiratory by Country
• Table 15 Gastrointestinal by Country
• Table 16 Blood by Country
• Table 17 Meningitis/Encephalitis by Country
• Table 18 Sexually Transmitted Disease by Country
• Table 19 Other by Country
• Table 20 Hospital Lab by Country
• Table 21 Outpatient Lab by Country
• Table 22 Point of Care by Country
• Table 23 Other by Country
• Table 24 Instruments by Country
• Table 25 Cartridges by Country
• Table 26 Reagents by Country
• Table 27 Other Product by Country
• Table 28 Clinical Lab Fee Schedule
• Table 29 The Most Common Assays
• Table 30 Largest Revenue Assays

Table of Figures

• Figure 1 Global health Spending
• Figure 2 The Road to Diagnostics
• Figure 3 Chart Death Rates and Infectious Disease Decline
• Figure 4 Centralized vs. Decentralized Laboratory Service
• Figure 5 A Highly Multiplexed Syndromic Testing Unit
• Figure 6 The Real Cost to Sequence the Human Genome
• Figure 7 The Codevelopment Process
• Figure 8 Comparing Syndromic and Targeted Testing
• Figure 9 The Multiplex Paradigm Shift
• Figure 10 Global Market Share Chart
• Figure 11 Global Market by Syndrome - Base vs. Final
• Figure 12 Global Market by Syndrome Base Year
• Figure 13 Global Market by Syndrome End Year
• Figure 14 Syndrome Share by Year
• Figure 15 Syndrome Segments Growth
• Figure 16 Global Market by Place - Base vs. Final
• Figure 17 Global Market by Place Base Year
• Figure 18 Global Market by Place End Year
• Figure 19 Place Share by Year
• Figure 20 Place Segments Growth
• Figure 21 Global Market by Product - Base vs. Final
• Figure 22 Global Market by Product Base Year
• Figure 23 Global Market by Product End Year
• Figure 24 Product Share by Year
• Figure 25 Product Segments Growth
• Figure 26 Respiratory Growth
• Figure 27 Gastrointestinal Diagnostics Growth
• Figure 28 Blood Growth
• Figure 29 Meningitis/Encephalitis Growth
• Figure 30 Sexually Transmitted Disease Growth
• Figure 31 Other Growth
• Figure 32 Hospital Lab Growth
• Figure 33 Outpatient Lab Growth
• Figure 34 Point of Care Growth
• Figure 35 Other Growth
• Figure 36 Instruments Growth
• Figure 37 Cartridges Growth
• Figure 38 Reagents Growth
• Figure 39 Other Product Growth